Effect of PPARγ2 Polymorphism and NSAIDs on Acute Alcohol-induced Changes in Serum Estrogens Among Post-menopausal Women

Breast Cancer Clinical Trial

— EPPNASE  

Official title:

Alcohol-related Breast Cancer in Postmenopausal Women - Effect of PPARG2pro12ala Polymorphism on Female Sex-hormone Levels and Interaction With Alcohol Consumption and NSAID Usage

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02463383
• Other study ID #: M215
• Status: Completed
• Phase: Early Phase 1
• First received: May 17, 2015
• Last updated: December 11, 2017
• Start date: September 2013
• Est. completion date: December 2015

Study information

• Verified date: December 2017
• Source: University of Copenhagen
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Postmenopausal women, stratified by a peroxisome proliferator-activated receptor gamma-2 (PPARG) polymorphism, were given the following treatments in a random order with a 5w wash-out period: a 400mg ibuprofen tablet or a placebo tablet; both treatments were followed after 30min by a single acute dose of 0.4g alcohol per kg bw. Serum estrogen levels were measured before and at three timepoints after alcohol intake. It is hypothesized that the acute decrease in estrogen sulphate and other markers of estrogens after alcohol intake is modulated by ibuprofen and by PPARG genotype.

Description:

In a pilot human intervention trial we aimed to determine the effect of the PPARG Pro12Ala polymorphism and the PPARγ stimulator, Ibuprofen, on sex-hormone levels following alcohol intake in postmenopausal women. Seven women with PPARG Pro12Ala and 18 PPARG wildtype women were included.The study was performed as a randomised, double-blinded, placebo controlled 2x24 h crossover study. The volunteers were randomised to 1 of 2 groups who got the two treatments in different orders. Treatment 1 was a placebo tablet with water followed after 30min by an alcoholic drink providing 0,4g alcohol per kilogram bw and treatment 2 was an Ibuprofen tablet (400mg) with water followed by the same alcoholic drink. The two treatments were separated by a 5-7 weeks washout period. Alcohol was supplied as 7.7% ethanol in a lime-flavoured drink and was consumed over 15 min. EDTA-plasma was collected 40min before and 30, 60 and 90 min after ethanol intake as well as after 24 hours. Ibuprofen (400mg) was provided together with 100mL water 30min before the ethanol. Urine was collected throughout the 24 hour interval. Serum estrone, estrone sulphate, serum estrogen-binding globulin (SHBG), and ethanol were determined. It is hypothesized that the acute decrease in estrogen sulphate and other markers of estrogens after alcohol intake is modulated by ibuprofen and by PPARG genotype.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 25
• Est. completion date: December 2015
• Est. primary completion date: October 2014
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 50 Years to 70 Years

Eligibility

Inclusion Criteria:

1. postmenopausal (last menses at least 1 year earlier);

2. having a weekly alcohol use of less than 14 drinks

3. having a BMI of 18-35;

Exclusion Criteria:

1. a history of alcohol abuse

2. alcohol abstaining

3. history of hysterectomy before last menses with preservation of both ovaries (unless a medical confirmation for the postmenopausal status exists or the participant is 60 years or older);

4. major health problems, such as ulcers, heart diseases, diabetes or cancer

5. previous or current use of HRT

6. taking prescription medications that could interfere with the study (i.e. daily use of NSAIDs and/or medication that interact with PPAR? e.g. cholesterol lowering medicine);

7. being allergic to alcohol and/or Ibuprofen

8. smoking

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Drug:
• Ibuprofen Tab 400 MG
400mg ibuprofen is provided and an alcohol challenge (0.4g/kg bw) is given 30min later
• Placebo tab
A placebo tablet is provided and an alcohol challenge (0.4g/kg bw) is given 30min later

Locations

Country	Name	City	State
Denmark	Department of Nutrition, Exercise and Sports, University of Copenhagen	Frederiksberg

Sponsors (2)

Lead Sponsor	Collaborator
Professor Lars Ove Dragsted	Technical University of Denmark

Country where clinical trial is conducted

Denmark, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Serum estrone sulphate (pmol/l)	Plasma estrone sulfate concentration after acute ethanol intake by Ibuprofen intake and/or PPARG genotype	from 40 min before to 90 min after alcohol consumption
Secondary	Serum estrone (pmol/l)	Plasma estrone decrease after acute ethanol intake by ibuprofen intake and/or PPARG genotype	from 40 min before to 90 min after alcohol consumption
Secondary	Serum SHBG (nmol/l)	Plasma SHBG concentration after acute ethanol ingestion by ibuprofen intake and/or PPARG genotype	from 40 min before to 90 min after alcohol consumption
Secondary	Serum ethanol (g/l)	Plasma ethanol concentration after acute ethanol ingestion	from 40 min before to 90 min after alcohol consumption
Secondary	Serum metabolomics (relative metabolite intensity)	The plasma metabolome profile by time after alcohol intake	from 40 min before to 24h after alcohol intake
Secondary	Urine metabolomics (relative metabolite intensity)	The urine metabolome profile by time after alcohol intake	from 40 min before to 24h after alcohol intake